Translational Research

Definiens Developer XD™ and Definiens Tissue Studio™ are being deployed at leading translational research and diagnostic laboratories worldwide, facilitating tasks such as: Quantification of predictive and prognostic tissue-based biomarkers; quantification of drug targets and disease markers, pre- and post-treatment; retrospective analysis of patient cohorts to reveal tissue attributes associated with clinical endpoints of interest.

Assays developed and validated with Definiens software seamlessly integrate into existing digital pathology workflows:

• Identify tissue-based biomarkers that are predictive or prognostic.
• Measure the effect of target protein expression, pre- and post-treatment.
• Quantify disease markers, pre- and post-treatment.
• Retrospective analysis to identify tissue biomarker and morphological traits associated with disease progression.
• Retrospective identification of therapeutic responders to identify biomarker and morphological traits associated with drug response.

For instance, Definiens has conducted several studies which have shown that the ability to analyze Her2/neu membrane biomarker expression on a true cell-by-cell basis, including a detailed analysis of subcellular morphology, significantly improves the accuracy of Dako Her2/neu-scores:

Comparative study on the Dako Her2/neu -score
Comparative study on survial prediction in esophageal cancer conducted with Helmholtz Institute